Diagnostic model of saliva peptide finger print analysis of primary Sjögren's syndrome patients by using weak cation exchange magnetic beads

• Published in: Bioscience reports Vol. 33; no. 4
• Main Authors: Wei, Pan, Kuo, Winston Patrick, Chen, Feng, Hua, Hong
• Format: Journal Article
• Language: English
• Published: England Portland Press Ltd 16.07.2013
• Subjects: Adult; Aged; Case-Control Studies; Chromatography, Ion Exchange; Female; Humans; Kininogens - chemistry; Kininogens - isolation & purification; Kininogens - metabolism; Magnetic Phenomena; Middle Aged; Molecular Weight; Original Paper; Peptides - chemistry; Peptides - isolation & purification; Peptides - metabolism; Saliva - metabolism; Sjogren's Syndrome - diagnosis; Sjogren's Syndrome - metabolism; Young Adult
• ISSN: 0144-8463; 1573-4935; 1573-4935
• DOI: 10.1042/BSR20130022

Saliva diagnostics has become an attractive field utilizing nanotechnology and molecular technologies for pSS (primary Sjögren's syndrome). However, no specific methods have been established. To refine the diagnostic power of the saliva peptide finger print for the early detection of pSS, we screened the expression spectrum of salivary peptides in pSS patients by using mass spectrometry MALDI-TOF-MS (matrix-assisted laser-desorption ionization-time-of-flight MS) combined with magnetic bead. The present study was comprised 12 pSS patients and 13 healthy controls and broken down to two different phases. In the initial ‘exploratory phase’, we enrolled seven pSS patients with eight age- and sex-matched healthy volunteers. Proteomics analysis of the unstimulated salivary samples was conducted to generate proportional peptide mass fingerprints. A diagnostic model was established. The testing cohort of the second ‘validation phase’ was represented by five pSS patients and five age- and sex-matched healthy controls. The diagnostic power of this diagnostic panel was then validated. The results showed seven m/z (mass-to-charge) ratio peaks with significant differences. Five peptides were up-regulated and two down-regulated in the pSS patients compared with matched healthy subjects. In the validation phase, four out of five pSS patients were diagnosed as pSS, and four of the five healthy controls were diagnosed as healthy controls, respectively. Potential biomarkers were also primarily predicted. The novel diagnostic proteomic model with m/z peaks 1068.1 Da, 1196.2 Da, 1738.4 Da, 3375.3 Da, 3429.3 Da, 3449.7 Da and 3490.6 Da is of certain value for early diagnosis of pSS.